Hung-Li Wang

 

 

王鴻利 (Hung-Li Wang) 

 

AppointmentProfessor and Chairman

LabMolecular Neuroscience Laboratory

EducationPh.D.

University/NationUniversity of Pennsylvania, USA

Tel: (03)2118800 ext.5060

E-mailhlwns@mail.cgu.edu.tw

Research website

Research outline Investigating cellular and molecular pathogenic mechanisms underlying hereditary neurological disorders, including Parkinson’s disease and spinocerebellar ataxia, with the aid of transgenic, knockout or knockin mouse model 

Publications (2015-):

  1. Chiu CC, Weng YH, Huang YZ, Chen RS, Liu YC, Yeh TH, Lu CS, Lin YW, Chen YJ, Hsu CC, Chiu CH, Wang YT, Chen WS, Liu SY, Wang HL* (2020) (D620N) VPS35 causes the impairment of Wnt/β-catenin signaling cascade and mitochondrial dysfunction in a PARK17 knockin mouse model. Cell Death and Disease, 11, 1018, doi:10.1038/s41419-020-03228-9.
  2. Liu YC, Wang HL (co-first author), Huang YZ, Weng YH, Chen RS, Tsai WC, Yeh TH, Lu CS, Chen YL, Lin YW, Chen YJ, Hsu CC, Chiu CH, Chiu CC (2020) Alda-1, an activator of ALDH2, ameliorates Achilles tendinopathy in cellular and mouse models. Biochemical Pharmacology, 175, 113919.
  3. Chiu CC, Yeh TH, Chen RS, Chen HC, Huang YZ, Weng YH, Cheng YC, Liu YC, Cheng AJ, Lu YC, Chen YJ, Lin YW, Hsu CC, Chen YL, Lu CS, Wang HL* (2019) Upregulated expression of microRNA-204-5p leads to the death of dopaminergic cells by targeting DYRK1A-mediated apoptotic signaling cascade. Frontiers in Cellular Neuroscience,13, 399-415.
  4. Chiu CC, Wang HL (co-first author), Weng YH, Chen RS, Chen CM, Yeh TH, Lu CS, Chen YJ, Liu YC, Huang YZ, Chang KH (2019) Generation of induced pluripotent stem cells from a young-onset Parkinson's disease patient carrying the compound heterozygous PLA2G6 p.D331Y/p.M358IfsX mutations. Stem Cell Research, 40, 101552.
  5. Wang HL, Lu CS, Yeh TH, Shen YM, Weng YH, Huang YZ, Chen RS, Liu YC, Cheng YC, Hsiu-Chen Chang HC, Chen YL, Chen YJ, Lin YW, Hsu CC, Lin HL, Chiu CH, Chiu CC (2019) Combined assessment of serum alpha-synuclein and Rab35 is a better biomarker for Parkinson's disease. Journal of Clinical Neurology, 15, 488-495.
  6. Chiu CC, Lu CS, Weng YH, Chen YL, Huang YZ, Chen RS, Cheng YC, Huang YC, Liu YC, Lai SC, Lin KJ, Lin YW, Chen YJ, Chen CL, Yeh TH, Wang HL* (2019) PARK14 (D331Y) PLA2G6 causes early-onset degeneration of substantia nigra dopaminergic neurons by inducing mitochondrial dysfunction, ER stress, mitophagy impairment and transcriptional dysregulation in a knockin mouse model. Molecular Neurobiology, 56, 3835-3853.
  7. Chiu CC, Yeh TH, Lu CS, Huang YC, Cheng YC, Huang YZ, Weng YH, Liu YC, Lai SC, Chen YL, Chen YJ, Chen CL, Chen HY, Lin YW, Wang HL* (2017) PARK14 PLA2G6 mutants are defective in preventing rotenone-induced mitochondrial dysfunction, ROS generation and activation of mitochondrial apoptotic pathway. Oncotarget, 8, 79046-79060.
  8. Chiu CC, Yeh TH, Lai SC, Weng YH, Huang YC, Cheng YC, Chen RS, Huang YZ, Hung J, Chen CC, Lin WY, Chang HC, Wu-Chou YH,  Chen YJ, Chen CL, Chen HY, Lin YW, Wang HL*, Lu CS (2016) Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson's disease. Oncotarget, 7, 54215-54227.
  9. Weng YH, Chen CY, Lin KJ, Chen YL, Yeh TH, Hsiao IT, Chen IJ, Lu CS, Wang HL* (2016) (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model. Experimental Neurology, 275, 104-115.
  10. Chou AH, Chen YL, Chiu CC, Yuan SJ, Weng YH, Yeh TH, Lin YL, Fang JM, Wang HL* (2015) T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse. Neuropharmacology, 99, 308-317.
  11. Chiu CC, Yeh TH, Lai SC, Wu-Chou YH, Chen CH, Mochly-Rosen D, Huang YC, Chen YJ, Chen CL, Chang YM, Wang HL*, Lu CS (2015) Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism. Experimental Neurology, 263, 244-253